Cutting Costs, Not Care: New Models for Affordable Men's Health Medications

The study evaluates the cost savings potential of the Mark Cuban Cost Plus Drug Company (CPDC) and GoodRx compared to Medicare for medications commonly prescribed for men's health issues such as erectile dysfunction, benign prostatic hyperplasia, premature ejaculation, and male infertility. Analyzing 9 drugs, including Tamsulosin and Sildenafil, the research found that Medicare's total spending in 2022 was $970 million. If these drugs were purchased through CPDC, costs could have been reduced to $760 million, $447 million, and $340 million for 30-, 60-, and 90-count fills, respectively. CPDC offered significant savings over Medicare for most drugs, particularly in erectile dysfunction treatments, and was generally cheaper than GoodRx, except for certain doses of paroxetine and tamsulosin. The study concludes that CPDC provides substantial cost savings on men's health medications compared to both Medicare and GoodRx.